Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This phase II clinical trial evaluated the efficacy, safety and pharmacokinetics of plitidepsin 3.2 mg/m(2) administered as a 1-hour intravenous infusion weekly on days 1, 8 and 15 every 4 weeks in 67 adult patients with relapsed/refractory aggressive non-Hodgkin's lymphoma. Patients were divided into two cohorts: those with non-cutaneous peripheral T-cell lymphoma (n=34) and those with other lymphomas (n=33). Efficacy was evaluated using the International Working Group criteria (1999). Of the 29 evaluable patients with non-cutaneous peripheral T-cell lymphoma, six had a response (overall response rate 20.7%; 95% confidence interval, 8.0%-39.7%), including two complete responses and four partial responses. No responses occurred in the 30 evaluable patients with other lymphomas (including 27 B-cell lymphomas). The most common plitidepsin-related adverse events were nausea, fatigue and myalgia (grade 3 in <10% of cases). Severe laboratory abnormalities (lymphopenia, anemia, thrombocytopenia, and increased levels of transaminase and creatine phosphokinase) were transient and easily managed by plitidepsin dose adjustments. The pharmacokinetic profile did not differ from that previously reported in patients with solid tumors. In conclusion, plitidepsin monotherapy has clinical activity in relapsed/refractory T-cell lymphomas. Combinations of plitidepsin with other chemotherapeutic drugs deserve further evaluation in patients with non-cutaneous peripheral T-cell lymphoma. (clinicaltrials.gov identifier: NCT00884286).
 ...
PMID:Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. 2306 25

A 50-year-old male without a relevant medical history came to the emergency department with fever, muscle pain and fatigue without any localising symptoms. Blood and urine cultures remained negative. Laboratory work- up showed elevated liver enzymes and lactate dehydrogenase; Epstein-Barr virus (EBV) serology was negative. Additional imaging showed a splenomegaly and cervical, axillary, mediastinal and hilar lymphadenopathy. Pathological examination of one of the lymph nodes and bone marrow biopsy revealed a peripheral T-cell non-Hodgkin's lymphoma not otherwise specified. Before the start of treatment he was asymptomatic, the laboratory results had normalised and the EBV polymerase chain reaction was strongly positive. Computed tomography scan was repeated and showed complete remission of the lymphadenopathy and normalised spleen volume. Follow-up bone marrow analysis including clonal rearrangement of the T-cell receptor after three months and one year revealed a decreasing clonal T-cell population (41%, 39% and 11% respectively). In conclusion, this was an extreme course of an EBV infection. The clinical relevance of the remaining small monoclonal T-cell population detectable in the bone marrow is unclear.
...
PMID:Epstein-Barr virus mimicking lymphoma--a case report. 2658 8


<< Previous 1 2